创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

张朝当, 徐希平. H型高血压2.0—药物研发与脑卒中精准预防[J]. 药学进展, 2019, 43(8): 567-575.
引用本文: 张朝当, 徐希平. H型高血压2.0—药物研发与脑卒中精准预防[J]. 药学进展, 2019, 43(8): 567-575.
ZHANG Chaodang, XU Xiping. H-type Hypertension 2.0—Development of Drugs Targeting the Precision Prevention of Stroke[J]. Progress in Pharmaceutical Sciences, 2019, 43(8): 567-575.
Citation: ZHANG Chaodang, XU Xiping. H-type Hypertension 2.0—Development of Drugs Targeting the Precision Prevention of Stroke[J]. Progress in Pharmaceutical Sciences, 2019, 43(8): 567-575.

H型高血压2.0—药物研发与脑卒中精准预防

H-type Hypertension 2.0—Development of Drugs Targeting the Precision Prevention of Stroke

  • 摘要: H型高血压是中国脑卒中持续高发的重要危险因素。中国脑卒中一级预防研究(CSPPT)是H型高血压药物研发1.0时代取得的重要进展,在世界上产生了重要的影响,获得国内外的广泛关注。鉴于不同基因型疗效差异和老年人群的代谢特点,H型高血压的治疗仍需要进一步细分,精准预防脑卒中得以提出,同时围绕同型半胱氨酸代谢通路联合多靶点用药也是潜在的研究方向。探讨H型高血压的成因、研发历程和目前的状况,以及未来研究的方向,以期为控制H型高血压预防脑卒中实现精准化。

     

    Abstract: H-type hypertension is an important risk factor for the persistently high morbidity of stroke in China. The CSPPT was an important breakthrough in the research and development of H-type hypertension drugs 1.0, with a significant impact attracting nationwide or even worldwide attention. The discovery of differences in the therapeutic efficacy between different genotypes and the consideration of the unique metabolic characteristics of the elderly have necessitated further patient stratification beyond H-type hypertension to achieve well-targeted prevention of stroke. The homocysteine metabolism pathway combined with multi-target drug therapy has opened up an exciting potential research direction. This paper discusses the causes, research history and current status of H-type hypertension, and summarizes direction for further research, aiming to facilitate the precision prevention and control of H-type hypertension and stroke.

     

/

返回文章
返回